Opinion|Videos|November 11, 2024
Multidisciplinary Care of HER2+ Breast Cancer: A Patient Perspective
Panelists discuss how a patient experienced care coordination during treatment at Memorial Sloan Kettering (MSK), detailing the health care professionals involved, the integration of services such as wound care and integrative medicine, and the positive impact of a team-based approach on her treatment experience and confidence in her care.
Advertisement
Episodes in this series
- Dr Iyengar asks Dorian Nygard: What did coordination of care look like from your perspective during your treatment at MSK?
- Which healthcare professionals did you meet with, and how were their efforts coordinated to support your care (e.g.eg, wound care, integrative medicine)?
- How did this team-based approach impact your treatment experience and overall confidence in your care?
Advertisement
Related to this article
Bhanu Prasad Venkatesulu, MBBS, MD, discussed why fewer radiation oncologists perform brachytherapy, and one setting where he considers it the better option.
Chinmay Jani, MD, discusses ASCO 2026 data on lung cancer trends in younger adults and why this group has been overlooked.
Data from the OrigAMI-4 trial support the accelerated approval of amivantamab and hyaluronidase-lpuj for this HNSCC population.
Bhanu Prasad Venkatesulu, MBBS, MD, discussed why fewer radiation oncologists offer prostate brachytherapy and the patients for whom he still recommends it.
Chinmay Jani, MD, explains how air pollution and asbestos contribute to lung cancer deaths beyond tobacco.
Claudine Isaacs, MD, and community oncologists weigh ASCENT-03 and ASCENT-04 data, crossover, and toxicity management with sacituzumab govitecan in TNBC.
The FDA assigned an April 9, 2027, target action date to resubmitted applications for rivoceranib plus camrelizumab in unresectable or metastatic hepatocellular carcinoma.
Adam C. Olson, MD, MSc-GH, discussed letting patients choose between modalities with comparably strong evidence, and the data that shaped his approach.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves SC Amivantamab for Recurrent/Metastatic HNSCC
2
FDA Sets PDUFA Date for Rivoceranib/Camrelizumab Resubmission After Third CRL in Unresectable HCC
3
Sacituzumab Govitecan Efficacy, Safety Debated in First-Line Metastatic TNBC
4
Air Pollution Emerges as Second Leading Risk Factor for Lung Cancer Deaths
5